Overall, we have demonstrated the important function of APE2 in the ATR-Chk1 DDR pathway in pancreatic cancer cells, which can be targeted for future combination or synthetic lethality therapies for cancers. This evidence concerns the gene CHEK1 and familial pancreatic carcinoma.